Drug intelligence / Profile preview

BI 891065

Development stage: Phase 1
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral

Overview

BI 891065 is a small-molecule SMAC (second mitochondria-derived activator of caspases) mimetic developed by Boehringer Ingelheim. It functions as an inhibitor of apoptosis protein (IAP) antagonist, designed to promote tumor cell death and enhance anti-tumor immune responses. By mimicking SMAC, it stimulates caspase activity and disrupts IAP-mediated inhibition of apoptosis in cancer cells. Preclinical data suggest that it may synergize with immune checkpoint inhibitors, making it a potential combination partner in cancer therapy, particularly for solid tumors such as colorectal cancer[1][2][7].

Other names: SMAC mimetic BI 891065

Targets

BIRC2 (Cellular inhibitor of apoptosis protein 1)BIRC3 (Baculoviral IAP repeat-containing protein 3)XIAP (Baculoviral IAP repeat-containing protein 4)

Beyond the preview

Go deeper on BI 891065.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 891065.

Explore the full profile